ARTICLE | Finance

Half-life extended

January 18, 2010 8:00 AM UTC

About a year ago, Nektar Therapeutics (NASDAQ:NKTR) was firmly in small cap territory, with a market cap around $365 million, and working on a post-Exubera turnaround. Last week, the company gained about $230 million in market cap to $1.1 billion on the latest in a string of good news.

Nektar disclosed the first Phase II data for its oncology candidate, NKTR-102, reporting positive preliminary data in ovarian cancer (see B16)...